Cilengitide (BioDeep_00000707038)
代谢物信息卡片
Cilengitide
化学式: C27H40N8O7 (588.3019810000001)
中文名称: 西仑吉肽
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
InChI: InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1
描述信息
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C2144 - Endothelial-Specific Integrin/Survival Signaling Inhibitor
D009676 - Noxae > D011042 - Poisons > D014688 - Venoms
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:177833
- KEGGdrug: D03497
- PubChem: 176873
- DrugBank: DB11890
- ChEMBL: CHEMBL429876
- CAS: 188968-51-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Danielle Nader, Nicola Fletcher, Gerard F Curley, Steven W Kerrigan. SARS-CoV-2 uses major endothelial integrin αvβ3 to cause vascular dysregulation in-vitro during COVID-19.
PloS one.
2021; 16(6):e0253347. doi:
10.1371/journal.pone.0253347. [PMID: 34161337] - Isabell Kemker, Christian Schnepel, David C Schröder, Antoine Marion, Norbert Sewald. Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.
Journal of medicinal chemistry.
2019 08; 62(16):7417-7430. doi:
10.1021/acs.jmedchem.9b00360. [PMID: 31306009] - Gian Luca Bagnato, Natasha Irrera, Gabriele Pizzino, Domenico Santoro, William Neal Roberts, Gianfilippo Bagnato, Giovanni Pallio, Mario Vaccaro, Francesco Squadrito, Antonino Saitta, Domenica Altavilla, Alessandra Bitto. Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis.
Clinical science (London, England : 1979).
2018 01; 132(2):231-242. doi:
10.1042/cs20171426. [PMID: 29237724] - Marco Tucci, Stefania Stucci, Claudia Felici, Paola Cafforio, Leonardo Resta, Roberta Rossi, Franco Silvestris. Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.
British journal of haematology.
2016 Apr; 173(1):59-69. doi:
10.1111/bjh.13922. [PMID: 26728969] - Ying-Zheng Zhao, Qian Lin, Ho Lun Wong, Xiao-Tong Shen, Wei Yang, He-Lin Xu, Kai-Li Mao, Fu-Rong Tian, Jing-Jing Yang, Jie Xu, Jian Xiao, Cui-Tao Lu. Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery.
Journal of controlled release : official journal of the Controlled Release Society.
2016 Feb; 224(?):112-125. doi:
10.1016/j.jconrel.2016.01.015. [PMID: 26792571] - Peter H O'Donnell, Sanja Karovic, Theodore G Karrison, Linda Janisch, Matthew R Levine, Pamela J Harris, Blase N Polite, Ezra E W Cohen, Gini F Fleming, Mark J Ratain, Michael L Maitland. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015 Nov; 21(22):5092-9. doi:
10.1158/1078-0432.ccr-15-0427. [PMID: 26199386] - Elizabeth R Gerstner, Xiaobu Ye, Dan G Duda, Michael A Levine, Tom Mikkelsen, Thomas J Kaley, Jeffrey J Olson, Burt L Nabors, Manmeet S Ahluwalia, Patrick Y Wen, Rakesh K Jain, Tracy T Batchelor, Stuart Grossman. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Neuro-oncology.
2015 Oct; 17(10):1386-92. doi:
10.1093/neuonc/nov085. [PMID: 26008604] - Andreas Becker, Oliver von Richter, Andreas Kovar, Holger Scheible, Jan J van Lier, Andreas Johne. Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.
Journal of clinical pharmacology.
2015 Jul; 55(7):815-24. doi:
10.1002/jcph.482. [PMID: 25683324] - Kristin Schneider, Astrid Weyerbrock, Soroush Doostkam, Karl Plate, Marcia Regina Machein. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
Journal of neuro-oncology.
2015 Jan; 121(2):269-78. doi:
10.1007/s11060-014-1647-3. [PMID: 25370707] - Christina S Mullins, Julia Schubert, Björn Schneider, Michael Linnebacher, Carl F Classen. Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.
Journal of cancer research and clinical oncology.
2013 Aug; 139(8):1425-31. doi:
10.1007/s00432-013-1457-6. [PMID: 23749036] - Stephanie M Cabarcas, Lei Sun, Lesley Mathews, Suneetha Thomas, Xiaohu Zhang, William L Farrar. The differentiation of pancreatic tumor-initiating cells by vitronectin can be blocked by cilengitide.
Pancreas.
2013 Jul; 42(5):861-70. doi:
10.1097/mpa.0b013e318279d568. [PMID: 23462327] - Tavarekere N Nagaraja, Madhava P Aryal, Stephen L Brown, Hassan Bagher-Ebadian, Tom Mikkelsen, James J Yang, Swayamprava Panda, Kelly A Keenan, Glauber Cabral, James R Ewing. Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.
PloS one.
2013; 8(12):e84493. doi:
10.1371/journal.pone.0084493. [PMID: 24376814] - Peter H O'Donnell, Samir D Undevia, Walter M Stadler, Theodore M Karrison, M Kelly Nicholas, Linda Janisch, Mark J Ratain. A phase I study of continuous infusion cilengitide in patients with solid tumors.
Investigational new drugs.
2012 Apr; 30(2):604-10. doi:
10.1007/s10637-010-9537-9. [PMID: 20839028] - Mark R Gilbert, John Kuhn, Kathleen R Lamborn, Frank Lieberman, Patrick Y Wen, Minesh Mehta, Timothy Cloughesy, Andrew B Lassman, Lisa M Deangelis, Susan Chang, Michael Prados. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
Journal of neuro-oncology.
2012 Jan; 106(1):147-53. doi:
10.1007/s11060-011-0650-1. [PMID: 21739168] - Rong Li, Meiping Ren, Ni Chen, Mao Luo, Zhuo Zhang, Jianbo Wu. Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions.
PloS one.
2012; 7(5):e37195. doi:
10.1371/journal.pone.0037195. [PMID: 22606350] - Stefan Rieken, Daniel Habermehl, Angela Mohr, Lena Wuerth, Katja Lindel, Klaus Weber, Jürgen Debus, Stephanie E Combs. Targeting ανβ3 and ανβ5 inhibits photon-induced hypermigration of malignant glioma cells.
Radiation oncology (London, England).
2011 Oct; 6(?):132. doi:
10.1186/1748-717x-6-132. [PMID: 21978494] - Gang Niu, Xiaoyuan Chen. Why integrin as a primary target for imaging and therapy.
Theranostics.
2011; 1(?):30-47. doi:
10.7150/thno/v01p0030. [PMID: 21544229] - Johanna Ivaska, Jyrki Heino. Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes.
Cell and tissue research.
2010 Jan; 339(1):111-20. doi:
10.1007/s00441-009-0857-z. [PMID: 19722108] - Eleonora Patsenker, Yury Popov, Felix Stickel, Vreni Schneider, Monika Ledermann, Hans Sägesser, Gerald Niedobitek, Simon L Goodman, Detlef Schuppan. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.
Hepatology (Baltimore, Md.).
2009 Nov; 50(5):1501-11. doi:
10.1002/hep.23144. [PMID: 19725105] - Tom Mikkelsen, Chaya Brodie, Susan Finniss, Michael E Berens, Jessica L Rennert, Kevin Nelson, Nancy Lemke, Stephen L Brown, Diane Hahn, Berend Neuteboom, Simon L Goodman. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
International journal of cancer.
2009 Jun; 124(11):2719-27. doi:
10.1002/ijc.24240. [PMID: 19199360] - Patrick T Caswell, May Chan, Andrew J Lindsay, Mary W McCaffrey, David Boettiger, Jim C Norman. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments.
The Journal of cell biology.
2008 Oct; 183(1):143-55. doi:
10.1083/jcb.200804140. [PMID: 18838556] - Tobey J MacDonald, Clinton F Stewart, Mehmet Kocak, Stewart Goldman, Richard G Ellenbogen, Peter Phillips, Deborah Lafond, Tina Young Poussaint, Mark W Kieran, James M Boyett, Larry E Kun. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2008 Feb; 26(6):919-24. doi:
10.1200/jco.2007.14.1812. [PMID: 18281665] - L Burt Nabors, Tom Mikkelsen, Steven S Rosenfeld, Fred Hochberg, Narasimha S Akella, Joy D Fisher, Gretchen A Cloud, Yu Zhang, Kathryn Carson, Sabine M Wittemer, A Dimitrios Colevas, Stuart A Grossman. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2007 May; 25(13):1651-7. doi:
10.1200/jco.2006.06.6514. [PMID: 17470857] - M E Cianfrocca, K A Kimmel, J Gallo, T Cardoso, M M Brown, G Hudes, N Lewis, L Weiner, G N Lam, S C Brown, D E Shaw, A P Mazar, R B Cohen. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.
British journal of cancer.
2006 Jun; 94(11):1621-6. doi:
10.1038/sj.bjc.6603171. [PMID: 16705310] - F A L M Eskens, H Dumez, R Hoekstra, A Perschl, C Brindley, S Böttcher, W Wynendaele, J Drevs, J Verweij, A T van Oosterom. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990).
2003 May; 39(7):917-26. doi:
10.1016/s0959-8049(03)00057-1. [PMID: 12706360]